Allergy Immunotherapy Market: By Treatment Type (Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy (SLIT), and Specific Immunotherapy (SIT)), By Allergy Type (Allergic Rhinitis, Asthma, Food Allergy, Venom Allergy, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy and Drug Stores, and Online Pharmacy) and Geography     

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

Allergy Immunotherapy Market size was valued at USD 2.1 billion in 2021 and is projected to reach USD 3.9 billion by 2028 at a CAGR of 9.2% during the forecast period 2022 to 2028. Owing to growing occurrence of sensitivities such as allergies and ineffective treatment procedures, such as pharmacotherapy, to control the prevalence rate of allergies are the major factors boosting the adoption of allergy immunotherapy Market, which is considered as a designated treatment for various types of allergies. Increasing death rates due to allergies is the main reason due to which government is supporting to invest in research and development to provide the better and improved treatment options for the patients. Allergy immunotherapy is a treatment that prevents allergic reactions from a variety of sources, including food, grass pollen, dust, and bee venom. Allergy immunotherapy helps people with allergies such as rhinitis, asthma, and conjunctivitis, among other allergies, regulate their symptoms. Allergy immunotherapy is regular injections that gradually increase the dosage in order to create resistance in the patient. Because of the increased creation of blocking antibodies that combat the foreign chemicals that cause allergies, the patient's immunity system becomes less brittle when the dosage is gradually increased.

Global Allergy Immunotherapy Market Summary

Study Period


Base Year




Largest Market


Fastest Growing Market


The prevalence of allergic patients are being increasing every year. According to the WAO (World Allergy Organization), a prominent growth in the ubiquity of allergies has been observed in the recent past. More than 30% of the total global population are suffering from allergic rhinitis. According to Health Statistics, around 8% of the U.S. adults suffer from sinusitis and hay fever. To create awareness among the population on allergies, number of government organizations came forward to support the program to create awareness among the population regarding the benefits of the allergy immunotherapy.

Key Features of the Reports

  • In January 2019, Sandoz Inc., has announced the U.S. market introduction of SYMJEP (epinephrine) 0.3 mg injection for the emergency treatment of allergic reactions (Type 1)
  • In June 2018, Aimmune Therapeutics, declared phase 3 trial results for AR101, an oral immunotherapy medication focused on peanut allergies, have met all the end points required by the U.S. Food and Drug Administration (FDA)

Global Allergy Immunotherapy Market Segmentation

By Treatment Type
  • Subcutaneous Immunotherapy (SCIT)
  • Sublingual Immunotherapy (SLIT)
  • Specific Immunotherapy (SIT)
By Allergy Type
  • Allergic Rhinitis
  • Asthma
  • Food Allergy
  • Venom Allergy
  • Others
Distribution Channel
  • Hospital Pharmacy
  • Retail Pharmacy and Drug Stores
  • Online Pharmacy
By Geography
North America
  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe
  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific
Latin America
  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America
Middle East and Africa (MEA)
  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

[urltag url='request-table-of-content']

  • Stallergenes Greer
  • ALK
  • Allergy Therapeutics
  • Merck KGaA
  • HAL Allergy B.V.
  • Biomay AG
  • Anergis
  • Aimmune Therapeutics
  • Circassia
  • DBV Technologies